BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jeuring SFG, van den Heuvel TRA, Liu LYL, Zeegers MP, Hameeteman WH, Romberg-camps MJL, Oostenbrug LE, Masclee AAM, Jonkers DMAE, Pierik MJ. Improvements in the Long-Term Outcome of Crohn’s Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort. American Journal of Gastroenterology 2017;112:325-36. [DOI: 10.1038/ajg.2016.524] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 13.8] [Reference Citation Analysis]
Number Citing Articles
1 Janssen L, Romberg-Camps M, van Bodegraven A, Haans J, Aquarius M, Boekema P, Munnecom T, Brandts L, Joore M, Masclee A, Jonkers D, Pierik M. Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial. BMJ Open 2021;11:e042885. [PMID: 33947729 DOI: 10.1136/bmjopen-2020-042885] [Reference Citation Analysis]
2 Biemans VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, Löwenberg M, de Boer NK, Oldenburg B, Srivastava N, Jansen JM, Bodelier AGL, West RL, de Vries AC, Haans JJL, de Jong D, Hoentjen F, Pierik MJ; Dutch Initiative on Crohn and Colitis (ICC). Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment. Aliment Pharmacol Ther 2020;52:123-34. [PMID: 32441396 DOI: 10.1111/apt.15745] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
3 Ford MM. Crohn's Disease Obstructions. Clin Colon Rectal Surg 2021;34:227-32. [PMID: 34305471 DOI: 10.1055/s-0041-1729926] [Reference Citation Analysis]
4 Beard JA, Franco DL, Click BH. The Burden of Cost in Inflammatory Bowel Disease: A Medical Economic Perspective and the Future of Value-Based Care. Curr Gastroenterol Rep 2020;22. [DOI: 10.1007/s11894-020-0744-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 De Simone B, Davies J, Chouillard E, Di Saverio S, Hoentjen F, Tarasconi A, Sartelli M, Biffl WL, Ansaloni L, Coccolini F, Chiarugi M, De'Angelis N, Moore EE, Kluger Y, Abu-Zidan F, Sakakushev B, Coimbra R, Celentano V, Wani I, Pintar T, Sganga G, Di Carlo I, Tartaglia D, Pikoulis M, Cardi M, De Moya MA, Leppaniemi A, Kirkpatrick A, Agnoletti V, Poggioli G, Carcoforo P, Baiocchi GL, Catena F. WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting. World J Emerg Surg 2021;16:23. [PMID: 33971899 DOI: 10.1186/s13017-021-00362-3] [Reference Citation Analysis]
6 Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics 2019;13:139-78. [PMID: 31440029 DOI: 10.2147/BTT.S207246] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
7 Chuah KH, Raja Ali RA, Hilmi IN. Decreasing major surgical rates for Crohn's disease in an emerging economy over two decades: Is it due to biologic therapy? Indian J Gastroenterol 2020;39:261-7. [PMID: 32613522 DOI: 10.1007/s12664-020-01044-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Stöss C, Berlet M, Reischl S, Nitsche U, Weber MC, Friess H, Wilhelm D, Neumann PA. Crohn's disease: a population-based study of surgery in the age of biological therapy. Int J Colorectal Dis 2021. [PMID: 33876296 DOI: 10.1007/s00384-021-03930-w] [Reference Citation Analysis]
9 Kichloo A, El-Amir Z, Dahiya DS, Wani F, Shaka H. Trends in hospitalizations and mortality for inflammatory bowel disease from a nationwide database study between 2008 and 2018. Proc (Bayl Univ Med Cent) 2021;34:550-4. [PMID: 34456471 DOI: 10.1080/08998280.2021.1919009] [Reference Citation Analysis]
10 Lie MRKL, Paulides E, van der Woude CJ. Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events. Int J Colorectal Dis 2020;35:1489-500. [PMID: 32592091 DOI: 10.1007/s00384-020-03663-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Beelen EMJ, van der Woude CJ, Pierik MJ, Hoentjen F, de Boer NK, Oldenburg B, van der Meulen AE, Ponsioen CIJ, Dijkstra G, Bruggink AH, Erler NS, Schouten WR, de Vries AC; Dutch Initiative on Crohn's and Colitis (ICC). Decreasing Trends in Intestinal Resection and Re-Resection in Crohn's Disease: A Nationwide Cohort Study. Ann Surg 2021;273:557-63. [PMID: 31188225 DOI: 10.1097/SLA.0000000000003395] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
12 Zhao M, Sall Jensen M, Knudsen T, Kelsen J, Coskun M, Kjellberg J, Burisch J. Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study. Aliment Pharmacol Ther 2021. [PMID: 34881439 DOI: 10.1111/apt.16723] [Reference Citation Analysis]
13 Cernoch PS, Fournier N, Zeitz J, Scharl M, Morell B, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; Swiss IBD Cohort Study Group. Lower Risk of B1-to-pB3-Stage Migration in Crohn's Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study. Dig Dis Sci 2020;65:2654-63. [PMID: 31797187 DOI: 10.1007/s10620-019-05978-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
14 Click B, Lopez R, Arrigain S, Schold J, Regueiro M, Rizk M. Shifting Cost-drivers of Health Care Expenditures in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2020;26:1268-75. [DOI: 10.1093/ibd/izz256] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
15 Liu W, Zhou W, Xiang J, Cao Q, Zhu J, Qi W, Chen P, Xie Q. Lémann Index at Diagnosis Predicts the Risk of Early Surgery in Crohn's Disease. Dis Colon Rectum 2018;61:207-13. [PMID: 29337776 DOI: 10.1097/DCR.0000000000000930] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Caparrós E, Wiest R, Scharl M, Rogler G, Gutiérrez Casbas A, Yilmaz B, Wawrzyniak M, Francés R. Dysbiotic microbiota interactions in Crohn's disease. Gut Microbes 2021;13:1949096. [PMID: 34313550 DOI: 10.1080/19490976.2021.1949096] [Reference Citation Analysis]
17 Khoudari G, Mansoor E, Click B, Alkhayyat M, Saleh MA, Sinh P, Katz J, Cooper GS, Regueiro M. Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients After Initiation of Biologics: A Cohort Study. Clinical Gastroenterology and Hepatology 2020. [DOI: 10.1016/j.cgh.2020.10.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
18 Wintjens D, Bergey F, Saccenti E, Jeuring S, van den Heuvel T, Romberg-Camps M, Oostenbrug L, Masclee A, Martins Dos Santos V, Jonkers D, Pierik M. Disease Activity Patterns of Crohn's Disease in the First Ten Years After Diagnosis in the Population-based IBD South Limburg Cohort. J Crohns Colitis 2021;15:391-400. [PMID: 32845291 DOI: 10.1093/ecco-jcc/jjaa173] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
19 Ditrich F, Blümel S, Biedermann L, Fournier N, Rossel JB, Ellinghaus D, Franke A, Stange EF, Rogler G, Scharl M; Swiss IBD Cohort Study Group. Genetic risk factors predict disease progression in Crohn's disease patients of the Swiss inflammatory bowel disease cohort. Therap Adv Gastroenterol 2020;13:1756284820959252. [PMID: 33281934 DOI: 10.1177/1756284820959252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Stenke E, Aviello G, Singh A, Martin S, Winter D, Sweeney B, McDermott M, Bourke B, Hussey S, Knaus UG. NADPH oxidase 4 is protective and not fibrogenic in intestinal inflammation. Redox Biol 2020;37:101752. [PMID: 33059312 DOI: 10.1016/j.redox.2020.101752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Zacharopoulou E, Craviotto V, Fiorino G, Furfaro F, Zilli A, Gilardi D, Peyrin-Biroulet L, Danese S, Allocca M. Targeting the gut layers in Crohn's disease: mucosal or transmural healing? Expert Rev Gastroenterol Hepatol 2020;14:775-87. [PMID: 32515627 DOI: 10.1080/17474124.2020.1780914] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Mehta SJ, Lewis A, Nijhuis A, Jeffery R, Biancheri P, Di Sabatino A, Feakins R, Silver A, Lindsay JO. Epithelial down-regulation of the miR-200 family in fibrostenosing Crohn's disease is associated with features of epithelial to mesenchymal transition. J Cell Mol Med. 2018;22:5617-5628. [PMID: 30188001 DOI: 10.1111/jcmm.13836] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
23 Jiang H, Shen J, Ran Z. Epithelial-mesenchymal transition in Crohn's disease. Mucosal Immunol. 2018;11:294-303. [PMID: 29346350 DOI: 10.1038/mi.2017.107] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
24 Pauwels RWM, van der Woude CJ, Nieboer D, Steyerberg EW, Casanova MJ, Gisbert JP, Kennedy NA, Lees CW, Louis E, Molnár T, Szántó K, Leo E, Bots S, Downey R, Lukas M, Lin WC, Amiot A, Lu C, Roblin X, Farkas K, Seidelin JB, Duijvestein M, D'Haens GR, de Vries AC; CEASE Study Group. Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00347-5. [PMID: 33933376 DOI: 10.1016/j.cgh.2021.03.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Lin XX, Qiu Y, Zhuang XJ, Liu F, Wu XM, Chen MH, Mao R. Intestinal stricture in Crohn's disease: A 2020 update. J Dig Dis 2021;22:390-8. [PMID: 34014617 DOI: 10.1111/1751-2980.13022] [Reference Citation Analysis]
26 van Linschoten RCA, Visser E, Niehot CD, van der Woude CJ, Hazelzet JA, van Noord D, West RL. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Aliment Pharmacol Ther 2021;54:234-48. [PMID: 34114667 DOI: 10.1111/apt.16445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:1075-106. [PMID: 29512050 DOI: 10.1007/s40262-018-0639-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
28 Elbadry M, Nour MO, Hussien M, Ghoneem EA, Medhat MA, Shehab H, Galal S, Eltabbakh M, El-raey F, Negm M, Afify S, Abdelhamed W, Sherief A, Abdelaziz A, Abo Elkasem M, Mahrous A, Kamal G, Maher M, Abdel-hameed O, Elbasuny A, El-zayyadi I, Bassiony A, Moussa A, Bedewy E, Elfert A, El Kassas M. Clinico-Epidemiological Characteristics of Patients With Inflammatory Bowel Disease in Egypt: A Nationwide Multicenter Study. Front Med 2022;9:867293. [DOI: 10.3389/fmed.2022.867293] [Reference Citation Analysis]
29 Chaparro M, Garre A, Núñez Ortiz A, Diz-Lois Palomares MT, Rodríguez C, Riestra S, Vela M, Benítez JM, Fernández Salgado E, Sánchez Rodríguez E, Hernández V, Ferreiro-Iglesias R, Ponferrada Díaz Á, Barrio J, Huguet JM, Sicilia B, Martín-Arranz MD, Calvet X, Ginard D, Alonso-Abreu I, Fernández-Salazar L, Varela Trastoy P, Rivero M, Vera-Mendoza I, Vega P, Navarro P, Sierra M, Cabriada JL, Aguas M, Vicente R, Navarro-Llavat M, Echarri A, Gomollón F, Guerra Del Río E, Piñero C, Casanova MJ, Spicakova K, Ortiz de Zarate J, Torrella Cortés E, Gutiérrez A, Alonso-Galán H, Hernández-Martínez Á, Marrero JM, Lorente Poyatos R, Calafat M, Martí Romero L, Robledo P, Bosch O, Jiménez N, Esteve Comas M, Duque JM, Fuentes Coronel AM, Josefa Sampedro M, Sesé Abizanda E, Herreros Martínez B, Pozzati L, Fernández Rosáenz H, Crespo Suarez B, López Serrano P, Lucendo AJ, Muñoz Vicente M, Bermejo F, Ramírez Palanca JJ, Menacho M, Carmona A, Camargo R, Torra Alsina S, Maroto N, Nerín de la Puerta J, Castro E, Marín-Jiménez I, Botella B, Sapiña A, Cruz N, Forcelledo JLF, Bouhmidi A, Castaño-Milla C, Opio V, Nicolás I, Kutz M, Abraldes Bechiarelli A, Gordillo J, Ber Y, Torres Domínguez Y, Novella Durán MT, Rodríguez Mondéjar S, Martínez-Cerezo FJ, Kolle L, Sabat M, Ledezma C, Iyo E, Roncero Ó, Irisarri R, Lluis L, Blázquez Gómez I, Zapata EM, José Alcalá M, Martínez Pascual C, Montealegre M, Mata L, Monrobel A, Hernández Camba A, Hernández L, Tejada M, Mir A, Galve ML, Soler M, Hervías D, Gómez-Valero JA, Barreiro-de Acosta M, Rodríguez-Artalejo F, García-Esquinas E, Gisbert JP, On Behalf Of The EpidemIBD Study Group Of Geteccu. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J Clin Med 2021;10:2885. [PMID: 34209680 DOI: 10.3390/jcm10132885] [Reference Citation Analysis]
30 Orlando S, Fraquelli M, Coletta M, Branchi F, Magarotto A, Conti CB, Mazza S, Conte D, Basilisco G, Caprioli F. Ultrasound Elasticity Imaging Predicts Therapeutic Outcomes of Patients With Crohn's Disease Treated With Anti-Tumour Necrosis Factor Antibodies. J Crohns Colitis 2018;12:63-70. [PMID: 28961950 DOI: 10.1093/ecco-jcc/jjx116] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
31 Limsrivilai J, Aniwan S, Sudcharoen A, Chaisidhivej N, Prueksapanich P, Pausawasdi N, Charatcharoenwitthaya P, Pongprasobchai S, Manassatit S. Temporal trend of disease recognition, treatment paradigm, and clinical outcomes of Crohn disease in Thailand from 2000 through 2017: Is early use of thiopurines beneficial? Medicine (Baltimore) 2020;99:e22216. [PMID: 32957358 DOI: 10.1097/MD.0000000000022216] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Hirschmann S, Fischer S, Klenske E, Dechant K, Distler JHW, Treutlein C, Neurath MF, Atreya R. Case report of severe constrictive perimyocarditis and ischemic hepatitis in a Crohn's disease patient upon infliximab-induced lupus-like syndrome. Therap Adv Gastroenterol 2021;14:17562848211044033. [PMID: 34616488 DOI: 10.1177/17562848211044033] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Burisch J, Vardi H, Schwartz D, Friger M, Kiudelis G, Kupčinskas J, Fumery M, Gower-Rousseau C, Lakatos L, Lakatos PL, D'Incà R, Sartini A, Valpiani D, Giannotta M, Arebi N, Duricova D, Bortlik M, Chetcuti Zammit S, Ellul P, Pedersen N, Kjeldsen J, Midjord JMM, Nielsen KR, Winther Andersen K, Andersen V, Katsanos KH, Christodoulou DK, Domislovic V, Krznaric Z, Sebastian S, Oksanen P, Collin P, Barros L, Magro F, Salupere R, Kievit HAL, Goldis A, Kaimakliotis IP, Dahlerup JF, Eriksson C, Halfvarson J, Fernandez A, Hernandez V, Turcan S, Belousova E, Langholz E, Munkholm P, Odes S; Epi-IBD group. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. Lancet Gastroenterol Hepatol 2020;5:454-64. [PMID: 32061322 DOI: 10.1016/S2468-1253(20)30012-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
34 Santiago M, Dias CC, Alves C, Ministro P, Gonçalves R, Carvalho D, Portela F, Correia L, Lago P, Magro F. The Magnitude of Crohn's Disease Direct Costs in Health Care Systems (from Different Perspectives): A Systematic Review. Inflamm Bowel Dis 2022:izab334. [PMID: 35179190 DOI: 10.1093/ibd/izab334] [Reference Citation Analysis]
35 Atia O, Orlanski-Meyer E, Lujan R, Ledderman N, Greenfeld S, Kariv R, Daher S, Yanai H, Loewenberg Weisband Y, Gabay H, Matz E, Nevo D, Israeli E, Schwartz D, Chowers Y, Dotan I, Turner D. Improved outcomes of pediatric and adult Crohn's disease and association with emerging use of biologics - a nationwide study from the epi-IIRN. J Crohns Colitis 2021:jjab204. [PMID: 34791083 DOI: 10.1093/ecco-jcc/jjab204] [Reference Citation Analysis]
36 Sleiman J, El Ouali S, Qazi T, Cohen B, Steele SR, Baker ME, Rieder F. Prevention and Treatment of Stricturing Crohn's Disease - Perspectives and Challenges. Expert Rev Gastroenterol Hepatol 2021;15:401-11. [PMID: 33225766 DOI: 10.1080/17474124.2021.1854732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Fuglestad MA, Thompson JS. Inflammatory Bowel Disease and Short Bowel Syndrome. Surg Clin North Am. 2019;99:1209-1221. [PMID: 31676059 DOI: 10.1016/j.suc.2019.08.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
38 Estrada HQ, Patel S, Rabizadeh S, Casero D, Targan SR, Barrett RJ. Development of a Personalized Intestinal Fibrosis Model Using Human Intestinal Organoids Derived From Induced Pluripotent Stem Cells. Inflamm Bowel Dis 2021:izab292. [PMID: 34918082 DOI: 10.1093/ibd/izab292] [Reference Citation Analysis]
39 Uda A, Kuwabara H, Shimizu S, Iwakiri R, Fushimi K. Optimal use of biologics with endoscopic balloon dilatation for repeated intestinal strictures in Crohn's disease. JGH Open 2020;4:532-40. [PMID: 32514466 DOI: 10.1002/jgh3.12329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Bamba S, Sakemi R, Fujii T, Takeda T, Fujioka S, Takenaka K, Kitamoto H, Umezawa S, Sakuraba H, Inokuchi T, Fukata N, Mizuno S, Yamashita M, Shinzaki S, Tanaka H, Takedatsu H, Ozaki R, Moriya K, Ishii M, Kinjo T, Ozeki K, Ooi M, Hayashi R, Kakimoto K, Shimodate Y, Kitamura K, Yamada A, Sonoda A, Nishida Y, Yoshioka K, Ashizuka S, Takahashi F, Shimokawa T, Kobayashi T, Andoh A, Hibi T. A nationwide, multi-center, retrospective study of symptomatic small bowel stricture in patients with Crohn’s disease. J Gastroenterol 2020;55:615-26. [DOI: 10.1007/s00535-020-01670-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
41 Biemans VBC, Savelkoul E, Gabriëls RY, Simsek M, Dijkstra G, Pierik MJ, West RL, de Boer NKH, Hoentjen F. A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients. Aliment Pharmacol Ther 2020;51:1076-86. [PMID: 32339331 DOI: 10.1111/apt.15730] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
42 Burisch J, Katsanos KH, Christodoulou DK, Barros L, Magro F, Pedersen N, Kjeldsen J, Vegh Z, Lakatos PL, Eriksson C, Halfvarson J, Fumery M, Gower-rousseau C, Brinar M, Čuković-čavka S, Nikulina I, Belousova E, Myers S, Sebastian S, Kiudelis G, Kupcinskas L, Schwartz D, Odes S, Kaimakliotis IP, Valpiani D, D’incà R, Salupere R, Chetcuti Zammit S, Ellul P, Duricova D, Bortlik M, Goldis A, Kievit HAL, Toca A, Turcan S, Midjord J, Nielsen KR, Andersen KW, Andersen V, Misra R, Arebi N, Oksanen P, Collin P, de Castro L, Hernandez V, Langholz E, Munkholm P; Epi-IBD Group. Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort—An Epi-IBD Study. Journal of Crohn's and Colitis 2019;13:198-208. [DOI: 10.1093/ecco-jcc/jjy154] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 10.8] [Reference Citation Analysis]
43 Rispo A, Imperatore N, Testa A, Bucci L, Luglio G, De Palma GD, Rea M, Nardone OM, Caporaso N, Castiglione F. Combined Endoscopic/Sonographic-based Risk Matrix Model for Predicting One-year Risk of Surgery: A Prospective Observational Study of a Tertiary Centre Severe/Refractory Crohn's Disease Cohort. J Crohns Colitis. 2018;12:784-793. [PMID: 29528382 DOI: 10.1093/ecco-jcc/jjy032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
44 Wang MH, Friton JJ, Raffals LE, Leighton JA, Pasha SF, Picco MF, Monroe K, Nix BD, Newberry RD, Faubion WA. Novel Genetic Variant Predicts Surgical Recurrence Risk in Crohn's Disease Patients. Inflamm Bowel Dis 2021:izaa362. [PMID: 33724339 DOI: 10.1093/ibd/izaa362] [Reference Citation Analysis]
45 Yu YR, Rodriguez JR. Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017;26:349-355. [PMID: 29126502 DOI: 10.1053/j.sempedsurg.2017.10.003] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 13.8] [Reference Citation Analysis]
46 Yassin S, Isakov NF, Ron Y, Cohen NA, Hirsch A, Maharshak N. A watchful waiting approach for newly diagnosed Crohn's disease patients with an inflammatory phenotype. Int J Colorectal Dis 2021;36:735-43. [PMID: 33404768 DOI: 10.1007/s00384-020-03811-8] [Reference Citation Analysis]
47 Jeuring SFG, Biemans VBC, van den Heuvel TRA, Zeegers MP, Hameeteman WH, Romberg-camps MJL, Oostenbrug LE, Masclee AAM, Jonkers DMAE, Pierik MJ. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era—Results from the Dutch Population-Based IBDSL Cohort. American Journal of Gastroenterology 2018;113:384-95. [DOI: 10.1038/ajg.2017.482] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
48 Holko P, Kawalec P, Pilc A. Impact of Biologic Treatment of Crohn's Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland. Front Pharmacol 2018;9:621. [PMID: 29942260 DOI: 10.3389/fphar.2018.00621] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
49 Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol. 2020;35:380-389. [PMID: 31596960 DOI: 10.1111/jgh.14872] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 14.7] [Reference Citation Analysis]
50 Rogler G, Hausmann M. Factors Promoting Development of Fibrosis in Crohn's Disease. Front Med (Lausanne) 2017;4:96. [PMID: 28736729 DOI: 10.3389/fmed.2017.00096] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
51 El Ouali S, Click B, Holubar SD, Rieder F. Natural history, diagnosis and treatment approach to fibrostenosing Crohn's disease. United European Gastroenterol J 2020;8:263-70. [PMID: 32213020 DOI: 10.1177/2050640620901960] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
52 Zhao M, Burisch J. The Sooner the Better? Cost-effectiveness of Early Biological Therapy in Patients With Crohn's Disease. J Crohns Colitis 2020;14:573-4. [PMID: 32556160 DOI: 10.1093/ecco-jcc/jjz192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Davies M, Dodd S, Coultate M, Ross A, Pears G, Gnaneswaran B, Tzivinikos C, Konidari A, Cheng J, Auth MK, Cameron F, Tamhne S, Renji E, Nair M, Baillie C, Collins P, Smith PJ, Subramanian S. From Paris to Montreal: disease regression is common during long term follow-up of paediatric Crohn’s disease. Scandinavian Journal of Gastroenterology 2020;55:148-53. [DOI: 10.1080/00365521.2019.1710765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Wang Z, Zhou H, Cheng F, Zhang Z, Long S. MiR-21 regulates epithelial–mesenchymal transition in intestinal fibrosis of Crohn's disease by targeting PTEN/mTOR. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.04.007] [Reference Citation Analysis]
55 Lo B, Vester-Andersen MK, Vind I, Prosberg M, Dubinsky M, Siegel CA, Bendtsen F, Burisch J. Changes in Disease Behaviour and Location in Patients With Crohn's Disease After Seven Years of Follow-Up: A Danish Population-based Inception Cohort. J Crohns Colitis. 2018;12:265-272. [PMID: 29506105 DOI: 10.1093/ecco-jcc/jjx138] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
56 Frei R, Fournier N, Zeitz J, Scharl M, Morell B, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L. Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study. J Crohns Colitis 2019;13:1292-301. [PMID: 30854548 DOI: 10.1093/ecco-jcc/jjz057] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
57 de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, Becx MC, Maljaars JP, Cilissen M, van Bodegraven AA, Mahmmod N, Markus T, Hameeteman WM, Dijkstra G, Masclee AA, Boonen A, Winkens B, van Tubergen A, Jonkers DM, Pierik MJ. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017;390:959-968. [PMID: 28716313 DOI: 10.1016/s0140-6736(17)31327-2] [Cited by in Crossref: 147] [Cited by in F6Publishing: 53] [Article Influence: 29.4] [Reference Citation Analysis]
58 Halligan S, Boone D, Archer L, Ahmad T, Bloom S, Rodriguez-Justo M, Taylor SA, Mallett S. Prognostic biomarkers to identify patients likely to develop severe Crohn's disease: a systematic review. Health Technol Assess 2021;25:1-66. [PMID: 34225839 DOI: 10.3310/hta25450] [Reference Citation Analysis]
59 Brown SR, Fearnhead NS, Faiz OD, Abercrombie JF, Acheson AG, Arnott RG, Clark SK, Clifford S, Davies RJ, Davies MM, Douie WJP, Dunlop MG, Epstein JC, Evans MD, George BD, Guy RJ, Hargest R, Hawthorne AB, Hill J, Hughes GW, Limdi JK, Maxwell-Armstrong CA, O'Connell PR, Pinkney TD, Pipe J, Sagar PM, Singh B, Soop M, Terry H, Torkington J, Verjee A, Walsh CJ, Warusavitarne JH, Williams AB, Williams GL, Wilson RG; ACPGBI IBD Surgery Consensus Collaboration. The Association of Coloproctology of Great Britain and Ireland consensus guidelines in surgery for inflammatory bowel disease. Colorectal Dis. 2018;20 Suppl 8:3-117. [PMID: 30508274 DOI: 10.1111/codi.14448] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
60 Senussi NH. Enteral Nutrition in the Treatment of Crohn's Disease: Overlooked and Underutilized. Am J Gastroenterol 2017;112:1751-2. [PMID: 29109488 DOI: 10.1038/ajg.2017.243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
61 Jenkinson PW, Plevris N, Siakavellas S, Lyons M, Arnott ID, Wilson D, Watson AJM, Jones GR, Lees CW. Temporal Trends in Surgical Resection Rates and Biologic Prescribing in Crohn's Disease: A Population-based Cohort Study. J Crohns Colitis 2020;14:1241-7. [PMID: 32840295 DOI: 10.1093/ecco-jcc/jjaa044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 Burisch J, Kiudelis G, Kupcinskas L, Kievit HAL, Andersen KW, Andersen V, Salupere R, Pedersen N, Kjeldsen J, D’incà R, Valpiani D, Schwartz D, Odes S, Olsen J, Nielsen KR, Vegh Z, Lakatos PL, Toca A, Turcan S, Katsanos KH, Christodoulou DK, Fumery M, Gower-rousseau C, Zammit SC, Ellul P, Eriksson C, Halfvarson J, Magro FJ, Duricova D, Bortlik M, Fernandez A, Hernández V, Myers S, Sebastian S, Oksanen P, Collin P, Goldis A, Misra R, Arebi N, Kaimakliotis IP, Nikuina I, Belousova E, Brinar M, Cukovic-cavka S, Langholz E, Munkholm P. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut 2019;68:423-33. [DOI: 10.1136/gutjnl-2017-315568] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 17.8] [Reference Citation Analysis]
63 Nagata Y, Esaki M, Moriyama T, Hirano A, Umeno J, Maehata Y, Torisu T, Matsumoto T, Kitazono T. Anti-tumor necrosis factor therapy decreases the risk of initial intestinal surgery after diagnosis of Crohn's disease of inflammatory type. J Gastroenterol 2019;54:330-8. [PMID: 30244398 DOI: 10.1007/s00535-018-1511-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
64 van den Heuvel TRA, Jeuring SFG, Zeegers MP, van Dongen DHE, Wolters A, Masclee AAM, Hameeteman WH, Romberg-camps MJL, Oostenbrug LE, Pierik MJ, Jonkers DM. A 20-Year Temporal Change Analysis in Incidence, Presenting Phenotype and Mortality, in the Dutch IBDSL Cohort—Can Diagnostic Factors Explain the Increase in IBD Incidence? Journal of Crohn's and Colitis 2017;11:1169-79. [DOI: 10.1093/ecco-jcc/jjx055] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
65 Levin A, Risto A, Myrelid P. The changing landscape of surgery for Crohn's disease. Seminars in Colon and Rectal Surgery 2020;31:100740. [DOI: 10.1016/j.scrs.2020.100740] [Reference Citation Analysis]
66 Soriano CR, Powell CR, Chiorean MV, Simianu VV. Role of hospitalization for inflammatory bowel disease in the post-biologic era. World J Clin Cases 2021; 9(26): 7632-7642 [PMID: 34621815 DOI: 10.12998/wjcc.v9.i26.7632] [Reference Citation Analysis]
67 Burisch J, Lophaven S, Langholz E, Munkholm P. The clinical course of Crohn's disease in a Danish population-based inception cohort with more than 50 years of follow-up, 1962-2017. Aliment Pharmacol Ther 2021. [PMID: 34543457 DOI: 10.1111/apt.16615] [Reference Citation Analysis]
68 Targownik LE, Tennakoon A, Leung S, Lix LM, Singh H, Bernstein CN. Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis. Clin Gastroenterol Hepatol 2017;15:1061-1070.e1. [PMID: 28238957 DOI: 10.1016/j.cgh.2017.01.035] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
69 Ochi M, Niikura R, Otsubo T, Yamada A, Kawai T, Koike K. Comparison of inflammatory bowel disease relapse after top-down or step-up therapy: a population-based cohort study. Int J Colorectal Dis 2021;36:2227-35. [PMID: 34386841 DOI: 10.1007/s00384-021-04007-4] [Reference Citation Analysis]
70 Bezzio C, Imperatore N, Armuzzi A, Rizzello F, Manes G, Bossa F, Calabrese E, Caprioli F, Daperno M, Mocciaro F, Orlando A, Papi C, Rispo A, Saibeni S; the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Barriers to anti‐TNFalpha prescription among Italian physicians managing inflammatory bowel disease. GastroHep 2019;1:93-9. [DOI: 10.1002/ygh2.331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
71 Lerang F, Holst R, Henriksen M, Wåhlberg H, Jelsness-jørgensen L. Antitumour necrosis factor alpha treatment in Crohn’s disease: long-term efficacy, side effects and need for surgery. Scandinavian Journal of Gastroenterology. [DOI: 10.1080/00365521.2022.2042592] [Reference Citation Analysis]
72 Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, Terdiman JP; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021;160:2496-508. [PMID: 34051983 DOI: 10.1053/j.gastro.2021.04.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
73 Mak JWY, Ng SC. Epidemiology of fibrostenosing inflammatory bowel disease. J Dig Dis 2020;21:332-5. [PMID: 32105396 DOI: 10.1111/1751-2980.12853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]